StreetAlpha.app
Home › Stocks › GRAL

GRAIL, Inc. (GRAL)

Healthcare
$99.25
▼ −5.33%
LAST CLOSE · NOV 20

GRAIL develops Galleri, a blood test that screens for many types of cancer at once. It last closed at $99.25 on Nov 20, down 5.33% on the day. The next earnings report for GRAL is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, GRAL reported EPS of -$2.21 on revenue of $37.5M, with revenue up 3.7% from a year ago. Over its last 8 reports the stock moved an average of 17.2% the session after earnings. Over the last 12 months GRAL insiders bought $0 of stock on the open market and sold $38.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is GRAL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GRAL.

Key Stats

Last 12 months
Results
Revenue
$166.6M
+17.5% vs a year ago
Net income
−$406.2M
−243.8% margin
EPS (diluted)
−$9.22
Free cash flow
−$312.0M
−187.3% margin
Valuation
Market cap
$4.5B
45.0M shares
P/E
–
No P/E while losing money
Price to sales
26.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.0M
At Sep 30
Shareholder equity
$2.5B
Shares outstanding
45.0M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $55.5M$55.5MFY2023FY2023: $93.1M$93.1MFY2023FY2024: $125.6M$125.6MFY2024FY2025: $147.2M$147.2MFY2025

From GRAL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$2.21
Quarter ended Sep 2026
Year ago EPS
-$2.46
Same quarter last year
Revenue
$37.5M
+3.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.93Dec '24Mar 2025: -$3.10Mar '25Jun 2025: -$3.18Jun '25Sep 2025: -$2.46Sep '25Dec 2025: -$2.38Dec '25Mar 2026: -$2.29Mar '26Jun 2026: -$2.56Jun '26Sep 2026: -$2.21Sep '26Latest -$2.21
Revenue by quarter
Dec 2024: $38.3MDec '24Mar 2025: $31.8MMar '25Jun 2025: $35.5MJun '25Sep 2025: $36.2MSep '25Dec 2025: $43.6MDec '25Mar 2026: $40.8MMar '26Jun 2026: $44.7MJun '26Sep 2026: $37.5MSep '26Latest $37.5M
How GRAL moved after its last 8 reports
Average move the session after a report ±17.2%
Nov 4, 2026After the close−17.1%
Aug 5, 2026After the close−14.5%
May 5, 2026After the close+15.3%
Feb 19, 2026After the close−50.5%
Jan 12, 2026Time not announced+5.8%
Oct 16, 2025After the close−9.7%
Aug 12, 2025After the close+1.1%
May 13, 2025After the close−23.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GRALStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GRAL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GRAL

Technical Analysis

GRAL · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 28% below its 20 day and 24% below its 50 day average. It is 20% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 36), near oversold. The nearest support is the 100 day average at $98.21, and the nearest resistance the Pivot at $100.52.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.6%/day
Key levels
$166.4752 week high+67.7%
$144.18Swing high (Oct 14)+45.3%
$127.0820 day average+28.0%
$123.3250 day average+24.3%
$102.69Pivot R1+3.5%
$100.52Pivot+1.3%
$99.25Last close
$98.21100 day average−1.0%
$97.09Pivot S1−2.2%
$79.27200 day average−20.1%
$76.60Swing low (Aug 31)−22.8%
$41.5052 week low−58.2%
Indicators
RSI (14)35.76Weak, oversold below 30Neutral
MACD-6.82Below its signal lineBearish
Stochastic5.8Near the bottom of its rangeOversold
ADX (14)27.0Trending down
Williams %R-98.1Oversold below −80, overbought above −20Oversold
CCI (20)-123.7Oversold below −100, overbought above 100Oversold
Rate of change−18.3%Change over 10 sessionsBearish
ATR (14)$10.52Typical daily range, 10.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for GRAL

What happened before

See how GRAL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for GRALHow many large options trades hit GRAL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

GRAL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲208 buying vs 168 selling
  • ▼Held by funds -1.9 pts
  • ▲Funds holding +70
  • ▲Superinvestors: 2 added, 1 cut
  • ▲Put/call 1.62 to 0.50
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding448378+18.5%
In funds' top 10103+233.3%
Held by funds85.1%87.0%−1.9 pts
New / increased108 / 10060 / 119+16.2%
Reduced / sold out129 / 3998 / 49+14.3%
Put/call ratio0.501.62−69.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GRAL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GRAL Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$38.3M21 sales · 4 insiders
28% of the selling was under pre-arranged trading plans.
2025-12 sold $7.6M2026-03 sold $4.0M2026-04 sold $11.5M2026-06 sold $91K2026-08 sold $1.1M2026-09 sold $6.4M2026-10 sold $7.3M2026-11 sold $323KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Aaron FreidinCFOSale plan3,000$107.62$323K
Oct 15Joshua J. OfmanCEOSale plan20,000$136.85$2.7M
Oct 5Aaron FreidinCFOSale23,619$146.39$3.5M
Oct 5Andrew John PartridgeChief Growth OfficerSale7,873$146.39$1.2M
Sep 21Joshua J. OfmanCEOSale plan61,452$97.74$6.0M
Sep 21Aaron FreidinCFOSale plan4,100$93.34$383K
Every insider buy and sale for GRAL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GRAL insider trades →

From SEC Form 4 filings by GRAL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GRAL is in one of them and how their past GRAL trades turned out.

GRAL in the AI portfolios
Loading…

GRAL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GRAL in an article yet. Here's the latest on the wider market.

GRAL in the news

About GRAIL

GRAIL is a healthcare company based in Sunnyvale, California, that develops blood tests for early cancer detection. Its main product, Galleri, screens for many types of cancer from a single blood draw and aims to indicate the organ or tissue where a cancer signal may come from. The company sells Galleri through partnerships with healthcare systems, employers, digital health platforms, payors and life insurance providers. Galleri is not yet approved by the U.S. Food and Drug Administration.

Headquarters
Sunnyvale, CA
Founded
2015